A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Sponsor: Alnylam

The APOLLO-B study focuses on heart failure caused by amyloidosis, specifically ATTR-cardiomyopathy. In this condition, the protein transthyretin breaks down and forms amyloid deposits between the heart muscle cells, impairing the heart’s function. The study investigates whether a medication called patisiran, which inhibits transthyretin production in the liver, can provide clinical benefit. The study recruited approximately 360 participants from 70 hospitals worldwide. The participants were divided into two groups: one receiving a placebo and the other receiving patisiran. Patisiran was administered via intravenous infusion every three weeks.

The study is closed for patient recruitment.

Study Team:
SI: drs. B.J. van Essen
Project coordinator: G.H. de Jong

People involved

Principal investigator

Peter van der Meer